

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in this application:

Claims 1-10 (cancelled).

Claim 11 (currently amended). An aptamer comprising a first nucleic acid sequence ~~that binds capable of binding~~ to a first target and a second nucleic acid sequence ~~that binds capable of binding~~ to a second target, wherein the said second sequence is an immunostimulatory CpG motif that stimulates an immune response, wherein the said CpG motif comprises the formula~~[[:]]~~ rCGyy, wherein “r” is a purine, “C” is cytosine, “G” is guanosine and “y” is a pyrimidine, and wherein the first sequence binds is capable of binding to a first target selected from the group consisting of PDGF, IgE, IgE Fc α R1, prostate-specific membrane antigen (PSMA), CD22, TNF-alpha, CTLA4, PD-1, PD-L1, PD-L2, FcRIIB, BTLA, transmembrane protein containing immunoglobulin and mucin-like domains domains (TIM-3), CD11c, B lymphocyte activating factor (BAFF), B7-X, CD19, CD20, CD25 and CD33.

Claims 12-13 (cancelled).

Claim 14 (currently amended). A pharmaceutical composition comprising ~~the an~~ aptamer ~~of claim~~~~according to~~ 11, a cytotoxic agent and a pharmaceutically acceptable carrier.

Claim 15 (currently amended). The composition of claim 14, wherein the cytotoxic agent belongs to a class of cytotoxic agents selected from the group consisting of tubulin stabilizers,

tubulin destabilizers, anti-metabolites, purine synthesis inhibitors, nucleoside analogs, DNA alkylating agents, DNA modifying agents[[,]] and vascular disrupting agents.

Claim 16 (currently amended). The composition of claim 14, wherein the cytotoxic agent is ~~used alone or in combinations of one or more cytotoxic agents~~ selected from the group consisting of calicheamycin, doxorubicin, taxol, methotrexate, gemcitabine, cytarabine, vinblastin, daunorubicin, docetaxel, irinotecan, epothilone B, epothilone D, cisplatin, carboplatin[[,]] and 5-fluoro-U.

Claims 17-64 (cancelled).